News – Page 1117 – Endpoints News

Novartis takes the long view on CAR-T, grabbing licenses on new tech for next-gen therapies

9 years ago

CureVac names a US subsidiary CEO to advance mRNA work; Sunesis shares slide after regulators nix drug app

9 years ago

Pfizer dumps a failed PhII Huntington’s drug in latest pipeline pruning

9 years ago

Little Abivax sees volatile shares rocket up on a (very early-stage) report of an HIV breakthrough

9 years ago

Hit-and-miss PhIIIs leave Lundbeck and Otsuka’s latest Alzheimer’s program in a precarious position

9 years ago

Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it

9 years ago

Welcome Imfinzi: AstraZeneca crashes the checkpoint party late with a green light for durvalumab

9 years ago

Intra-Cellular takes another beating after the FDA raises a red flag on schizophrenia drug safety

9 years ago

Robert Plenge tapped to run immunology R&D at Celgene; Tesaro files LAG-3 IND

9 years ago

Aeterna Zentaris shares eviscerated by its latest late-stage drug disaster

9 years ago

Following Vertex pact, Parion strikes another rich collaboration — this time with Shire

9 years ago

Little Neurotrope makes some big claims on another failed Alzheimer’s study, but shares collapse

9 years ago

With Amgen hot on its heels, Radius races to get a jump on osteoporosis drug rivalry

9 years ago

Takeda gets a potential blockbuster bonus on $5B Ariad deal with FDA’s approval of brigatinib

9 years ago

Novartis bags FDA OK for Rydapt, adding a new chemo combo drug for AML

9 years ago

Novartis vet named CMO at Rgenix; Ophthotech promotes Sblendorio to CEO spot

9 years ago

Scott Gottlieb will push to publish CRLs; Marathon's demise offers the industry a cautionary tale

9 years ago

Bristol-Myers passed on its $475M deal to option F-star drug; Zymeworks IPO raises $59M

9 years ago

Tom Lynch outlines his comeback strategy for Bristol-Myers’ badly bruised R&D organization

9 years ago

The new top 10 most expensive drugs on the planet

9 years ago

Ed Kaye preps a surprising exit from Sarepta, spurring chatter about a possible sale

9 years ago

Not so crazy now: Biotech’s most closely watched unicorn just produced its first clear snapshot of human efficacy ...

9 years ago

BioMarin scores a quick FDA OK for its latest rare disease entry — flagged at $702K WAC

9 years ago

Senate committee backs Scott Gottlieb as next FDA commissioner

9 years ago

First page Previous page 1114 1115 111611171118 1119 1120 Next page Last page